Cancer metallo‐immunotherapy can modulate the inherent host and tumor immune signals via metal ions, such as Zn2+/Mn2+ for amplifying STING activation, Ca2+ for T‐cell activation involving lipid regulation, and Fe2+, K+, Ca2+, and Na+ for inflammasome activation, to interfere with cancer progression.[8] Studies have also shown that Mn2+ ions can sensitize the cGAS‐STING pathway, synergizing with cancer phototherapy, chemotherapy, and immunotherapy.[9] Moreover, low serum magnesium levels are closely related to fast disease progression and short overall survival during immunotherapy. The gene discussed is STING1; the disease is neoplasm.